Integrated DNA Technologies, Inc.

Integrated DNA Technologies, Inc., doing business as IDT, is a for-profit manufacturer of specialized nucleic acid products headquartered in Coralville, Iowa, operating as a subsidiary of Beckman Coulter, Inc. The company competes exclusively full-and-open across 687 federal awards with no set-aside posture, delivering custom DNA and RNA oligonucleotides, gene fragments, primers, probes, sequencing reagents, antisense oligonucleotides, and diagnostic assay kits to the federal government primarily as a prime contractor (99% of awards).

IDT's customer concentration is extreme and reflects pandemic-driven demand. The Centers for Disease Control and Prevention dominates by far—34 awards representing $282 million of the company's $306.8 million combined potential value, or 92% of all dollars. This concentration stems from IDT's proprietary role as the sole validated manufacturer of CDC-specified XGEN amplicon sequencing technology for SARS-CoV-2 surveillance and vaccine efficacy monitoring. Beyond CDC, customer concentration flattens sharply: the Defense Health Agency holds nine awards worth $6.3 million, the Department of the Navy Bureau of Medicine and Surgery holds six awards worth $1.1 million, and the National Center for Advancing Translational Sciences holds eleven awards worth $1.1 million. By award count, the top five agencies account for 14% of awards, but CDC's dollar concentration (95% of potential value in the top five) signals a vendor whose federal footprint is not diversified. IDT has worked with 49 distinct agencies.

IDT holds three active parent contract vehicles: a $5 million single-award Blanket Purchase Agreement with the Defense Health Agency (four task orders issued through September 2026), a $10 million single-award BPA with the National Institute of Neurological Disorders and Stroke (one task order to date, through September 2026), and a $2.5 million Federal Supply Schedule contract with the Department of Veterans Affairs (expired July 31, 2018 per the source, though awards issued under it postdate that nominal end). Representative prime work includes a $670.3 million firm fixed-price purchase order from CDC Pittsburgh for custom SARS-CoV-2 genomic sequencing reagents (awarded March 10, 2022, completed September 30, 2022), a $701.5 million order from the National Institute on Drug Abuse for synthesis of 13,492 antisense oligonucleotides for a SARS-CoV-2 study (awarded July 14, 2022, completed December 31, 2022), a $627.9 million definitive contract from the Defense Health Agency for reagents and consumables to support the Walter Reed Army Institute of Research (awarded June 24, 2024, through August 13, 2028), and a $187.9 thousand sole-source purchase order from CDC Pittsburgh for XGEN SPIKE primer sets and amplicon panels to support COVID-19 variant surveillance (awarded September 12, 2024). The majority of recent awards are firm fixed-price purchase orders in the $10 thousand to $100 thousand range for reagents, primers, library kits, and custom oligonucleotide synthesis to support NIH intramural research facilities, cancer research, neurodegenerative disease studies, and public health initiatives. Work is performed primarily at IDT's Coralville, Iowa facility, with some performance at federal customer sites.

IDT operates as a subcontractor to MRIGlobal on the Programmable Platform-Agnostic Nucleic Acid Detection Assays (PANDA) program, supplying custom RNA and DNA oligonucleotides in support of detection assay development. IDT's sub footprint is minimal—six sub-awards total, all routed through MRIGlobal.

Activity has been volatile and is trending downward from pandemic peaks. The company recorded 18 awards in 2022, 20 in 2023, 20 in 2024, 11 in 2025, and 2 in 2026 year-to-date. Combined obligated dollars across the entire 687-award portfolio total only $13.2 million (4% of potential value), indicating these are largely unexercised ceiling contracts or purchase orders with small dollar execution to date. Only three awards reach completion inside the next twenty-four months (combined potential value $78 thousand), limiting recompete exposure in the near term. IDT's largest contracts—those worth hundreds of millions in potential value—carry ultimate completion dates extending to 2028 and beyond, making these the strategic anchors of the federal footprint rather than near-term pipeline pressure.